Document

WESTLAKE, Ohio--(BUSINESS WIRE)--August 18, 2025--Nordson Corporation (Nasdaq: NDSN) today reported results for the fiscal third quarter ended July 31, 2025. Sales were $742 million compared to the prior year’s third quarter sales of $662 million. The third quarter 2025 sales included a favorable acquisition impact of 8%, an organic sales increase of 2% and a favorable currency translation impact of 2%.

Net income was $126 million, or $2.22 of earnings per diluted share, compared to prior year’s third quarter net income of $117 million, or $2.04 of earnings per diluted share. Excluding charges associated with the exit of the medical contract manufacturing business and acquisition-related amortization and costs, third quarter adjusted net income was $155 million versus prior year adjusted net income of $138 million. Third quarter adjusted earnings per diluted share were $2.73, a 13% increase from the prior year adjusted earnings per diluted share of $2.41.

Commenting on the Company’s fiscal 2025 third quarter results, Nordson President and Chief Executive Officer Sundaram Nagarajan said, “The Nordson team responded effectively to dynamic demand conditions in key end markets and delivered on its promises, realizing solid year-over-year organic growth in the quarter. In particular, the Advanced Technology Solutions segment delivered 15% organic sales growth. Operational excellence drove strong profit performance, increasing adjusted earnings per share by 13% and EBITDA by 15%. In this final full quarter of Atrion’s first year acquisition performance, our new employees again exceeded expectations and contributed to both sales and earnings results. Also this quarter, we maintained a strong balance sheet, delivering cash flow conversion of 180% of net income that we used to reduce debt, repurchase shares and return dividends to shareholders, while continuing to invest in the company.”

Industrial Precision Solutions sales of $351 million increased 1% from the prior year, inclusive of an organic sales decrease of 2% and favorable currency translation of 3%. The organic sales decrease was driven by weaker systems demand in polymer processing offsetting growth in most other product lines. Operating profit was $117 million, an increase of $2 million from the prior year. EBITDA in the quarter was $130 million, or 37% of sales, compared to prior year third quarter EBITDA of $131 million, or 37% of sales.

Medical and Fluid Solutions sales of $219 million increased 32% compared to the prior year third quarter, inclusive of an acquisition impact of 31% and a favorable currency impact of 1%. Organic sales were flat inclusive of the contract manufacturing business that is held for sale. Excluding the pending divestiture in both periods, organic sales increased 4% driven by medical fluid components and fluid solutions product lines. Operating profit was $53 million, an increase of $4 million from the prior year. Excluding acquisition costs and charges associated with the exit of the medical contract manufacturing business, operating profit was $65 million, an increase of $17 million from the prior year reflecting increased leverage of selling, general and administrative expenses in the core business, as well as contribution from the Atrion acquisition. EBITDA in the quarter was $83 million, or 38% of sales, up 34% versus the prior year third quarter EBITDA of $62 million, or 37% of sales.

Backlog is down approximately 5% sequentially following a strong third quarter. This supports achieving the Company’s original full year sales and earnings guidance, assuming completion of the pending divestiture of the medical contract manufacturing business in the fourth quarter. Fiscal full year sales are now tracking slightly below the mid-point and full year adjusted earnings per share are now tracking slightly above the mid-point of our original guidance.

Reflecting on the full year outlook, Nagarajan said, “Following a strong third quarter, I am pleased that we are able to affirm our full year sales guidance and earnings expectations. NBS Next is driving organic growth by enhancing our new product vitality, best-in-class quality and delivery, while also empowering our teams to respond quickly to changing customer demand. Through our close-to-customer business model, diverse product portfolio and in-region, for-region manufacturing strategy, we have continuously demonstrated resilience and the ability to deliver solid growth and best-in-class profitability in varying market scenarios.”

Nordson management will provide additional commentary on these results and outlook during its previously announced webcast on Thursday, August 21, 2025, at 8:30 a.m. eastern time, which can be accessed at https://investors.nordson.com. Information about Nordson’s investor relations and shareholder services is available from Lara Mahoney, vice president, investor relations and corporate communications at (440) 204-9985 or lara.mahoney@nordson.com.

The Company’s definition of adjusted earnings excludes restructuring, business exit and acquisition related cost / amortization for both current and historical periods. It is not possible for the Company to identify the amount or significance of future adjustments associated with acquisition and integration costs, restructuring costs, acquisition-related amortization, certain non-operating or income tax items, or other non-routine costs that the Company adjusts in the presentation of adjusted earnings guidance. These items are dependent on future events that are not reasonably estimable at this time. Accordingly, the Company is unable to reconcile without unreasonable effort the forecasted range of adjusted earnings guidance to a comparable GAAP range.

Certain statements contained in this release are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by terminology such as “may,” “will,” “should,” “could,” “expects,” “anticipates,” “believes,” “projects,” “forecasts,” “outlook,” “guidance,” “continue,” “target,” or the negative of these terms or comparable terminology. These statements reflect management’s current expectations and involve a number of risks and uncertainties. These risks and uncertainties include, but are not limited to, U.S. and international economic and political conditions; financial and market conditions; currency exchange rates and devaluations; possible acquisitions and the Company’s ability to successfully integrate acquisitions; the Company’s ability to successfully divest or dispose of businesses that are deemed not to fit with its strategic plan; the effects of changes in U.S. trade policy and trade agreements, including changes in tariffs by the U.S. or other nations; the effects of changes in tax law; and the possible effects of events beyond our control, such as political unrest, including the conflicts in Europe and the Middle East, acts of terror, natural disasters and pandemics and the other factors discussed in Item 1A (Risk Factors) in the Company’s most recently filed Annual Report on Form 10-K and in its Forms 10-Q filed with the Securities and Exchange Commission, which should be reviewed carefully. The Company undertakes no obligation to update or revise any forward-looking statement in this press release.

Nordson Corporation is an innovative precision technology company that leverages a scalable growth framework through an entrepreneurial, division-led organization to deliver top tier growth with leading margins and returns. The Company’s direct sales model and applications expertise serves global customers through a wide variety of critical applications. Its diverse end market exposure includes consumer non-durable, medical, electronics and industrial end markets. Founded in 1954 and headquartered in Westlake, Ohio, the Company has operations and support offices in over 35 countries. Visit Nordson on the web at www.nordson.com, linkedin/Nordson, or www.facebook.com/nordson.


	Three Months Ended						Nine Months Ended
	July 31, 2025			July 31, 2024			July 31, 2025			July 31, 2024

Sales	$	741,509		$	661,604		$	2,039,867		$	1,945,439
Cost of sales	334,992			292,603			923,550			862,134
Gross profit	406,517			369,001			1,116,317			1,083,305
Gross margin %	54.8		%	55.8		%	54.7		%	55.7		%

Selling & administrative expenses	206,539			201,943			606,642			588,196
Divestiture and related charges	12,211			—			12,211			—
Operating profit	187,767			167,058			497,464			495,109

Interest expense - net	(25,698)			(17,776)			(77,335)			(56,729)
Other income (expense) - net	(2,945)			152			(5,380)			(971)
Income before income taxes	159,124			149,434			414,749			437,409

Income taxes	33,340			32,107			81,909			92,293

Net income	$	125,784		$	117,327		$	332,840		$	345,116

Weighted-average common shares outstanding:
Basic	56,438			57,229			56,784			57,171
Diluted	56,728			57,624			57,084			57,620

Earnings per share:
Basic earnings	$	2.23		$	2.05		$	5.86		$	6.04
Diluted earnings	$	2.22		$	2.04		$	5.83		$	5.99


	July 31, 2025		October 31, 2024

Cash and cash equivalents	$	147,788	$	115,952
Receivables - net	588,951		594,663
Inventories - net	459,251		476,935
Other current assets	91,275		87,482
Assets held for sale	39,583		—
Total current assets	1,326,848		1,275,032

Property, plant and equipment - net	525,604		544,607
Goodwill	3,306,432		3,280,819
Other assets	850,829		900,508
	$	6,009,713	$	6,000,966

Notes payable and debt due within one year	$	336,078	$	103,928
Accounts payable and accrued liabilities	436,223		424,549
Liabilities held for sale	10,807		—
Total current liabilities	783,108		528,477

Long-term debt	1,785,745		2,101,197
Other liabilities	459,075		439,100
Total shareholders' equity	2,981,785		2,932,192
	$	6,009,713	$	6,000,966


	Nine Months Ended
	July 31, 2025		July 31, 2024
Cash flows from operating activities:
Net income	$	332,840	$	345,116
Depreciation and amortization	112,454		99,646
Divestiture and related charges	12,211		—
Other non-cash items	12,154		15,435
Changes in operating assets and liabilities and other	46,605		(385)


Net cash provided by operating activities	516,264		459,812

Cash flows from investing activities:
Additions to property, plant and equipment	(49,002)		(43,786)

Other - net	4,272		8,896
Net cash used in investing activities	(44,730)		(34,890)

Cash flows from financing activities:
Repayment of long-term debt - net	(94,664)		(244,355)
Repayment of finance lease obligations	(4,083)		(4,505)
Dividends paid	(133,008)		(116,789)
Issuance of common shares	5,419		29,142
Purchase of treasury shares	(218,194)		(34,105)
Net cash used in financing activities	(444,530)		(370,612)

Effect of exchange rate change on cash:	4,832		(4,665)
Net change in cash and cash equivalents	31,836		49,645

Cash and cash equivalents:
Beginning of period	115,952		115,679
End of period	$	147,788	$	165,324


	Three Months Ended				Sales Variance
	July 31, 2025		July 31, 2024		Organic		Acquisitions		Currency		Total
SALES BY SEGMENT
Industrial Precision Solutions	$	350,784	$	348,997	(2.0)	%	—	%	2.5	%	0.5	%
Medical and Fluid Solutions	219,465		166,737		(0.4)	%	31.0	%	1.0	%	31.6	%
Advanced Technology Solutions	171,260		145,870		14.6	%	—	%	2.8	%	17.4	%
Total sales	$	741,509	$	661,604	2.1	%	7.8	%	2.2	%	12.1	%

SALES BY GEOGRAPHIC REGION
Americas	$	314,568	$	287,016	(3.2)	%	13.0	%	(0.2)	%	9.6	%
Europe	186,620		179,370		(6.1)	%	4.8	%	5.3	%	4.0	%
Asia Pacific	240,321		195,218		17.4	%	2.9	%	2.8	%	23.1	%
Total sales	$	741,509	$	661,604	2.1	%	7.8	%	2.2	%	12.1	%


	Nine Months Ended				Sales Variance
	July 31, 2025		July 31, 2024		Organic		Acquisitions		Currency		Total
SALES BY SEGMENT
Industrial Precision Solutions	$	970,079	$	1,031,717	(5.7)	%	—	%	(0.3)	%	(6.0)	%
Medical and Fluid Solutions	615,883		495,229		(7.1)	%	31.5	%	—	%	24.4	%
Advanced Technology Solutions	453,905		418,493		8.0	%	—	%	0.5	%	8.5	%
Total sales	$	2,039,867	$	1,945,439	(3.1)	%	8.1	%	(0.1)	%	4.9	%

SALES BY GEOGRAPHIC REGION
Americas	$	874,868	$	855,456	(10.0)	%	13.1	%	(0.8)	%	2.3	%
Europe	526,878		540,750		(8.7)	%	5.0	%	1.1	%	(2.6)	%
Asia Pacific	638,121		549,233		13.1	%	3.1	%	—	%	16.2	%
Total sales	$	2,039,867	$	1,945,439	(3.1)	%	8.1	%	(0.1)	%	4.9	%


	Three Months Ended				Nine Months Ended
	July 31, 2025		July 31, 2024		July 31, 2025		July 31, 2024
Net income	$	125,784	$	117,327	$	332,840	$	345,116
Income taxes	33,340		32,107		81,909		92,293
Interest expense - net	25,698		17,776		77,335		56,729
Other (income) expense - net	2,945		(152)		5,380		971
Depreciation and amortization	37,847		33,382		112,454		99,646
Inventory step-up amortization (1)	—		—		3,135		2,944
Severance and other (1)	451		2,536		16,725		4,615
Acquisition-related costs (1)	235		5,160		1,778		5,757
Divestiture and related charges (2)	12,211		—		12,211		—
EBITDA (non-GAAP) (3)	$	238,511	$	208,136	$	643,767	$	608,071


	Three Months Ended						Nine Months Ended
	July 31, 2025			July 31, 2024			July 31, 2025			July 31, 2024
SALES BY SEGMENT
Industrial Precision Solutions	$	350,784		$	348,997		$	970,079		$	1,031,717
Medical and Fluid Solutions	219,465			166,737			615,883			495,229
Advanced Technology Solutions	171,260			145,870			453,905			418,493
Total sales	$	741,509		$	661,604		$	2,039,867		$	1,945,439

OPERATING PROFIT
Industrial Precision Solutions	$	116,720		$	115,023		$	308,153		$	340,043
Medical and Fluid Solutions	52,500			48,374			150,241			143,467
Advanced Technology Solutions	36,877			26,032			86,558			65,029
Corporate	(18,330)			(22,371)			(47,488)			(53,430)
Total operating profit	$	187,767		$	167,058		$	497,464		$	495,109

OPERATING PROFIT ADJUSTMENTS (1)
Industrial Precision Solutions	$	—		$	2,536		$	9,823		$	6,077
Medical and Fluid Solutions	12,968			—			19,589			—
Advanced Technology Solutions	(71)			—			3,217			2,078
Corporate	—			5,160			1,220			5,161
Total adjustments	$	12,897		$	7,696		$	33,849		$	13,316








DEPRECIATION & AMORTIZATION
Industrial Precision Solutions	$	13,410		$	13,047		$	38,477		$	38,404
Medical and Fluid Solutions	17,685			13,553			54,193			40,822
Advanced Technology Solutions	4,740			4,841			14,058			14,509
Corporate	2,012			1,941			5,726			5,911
Total depreciation & amortization	$	37,847		$	33,382		$	112,454		$	99,646

EBITDA (NON-GAAP) (2)
Industrial Precision Solutions	$	130,130	37%	$	130,606	37%	$	356,453	37%	$	384,524	37%
Medical and Fluid Solutions	83,153		38%	61,927		37%	224,023		36%	184,289		37%
Advanced Technology Solutions	41,546		24%	30,873		21%	103,833		23%	81,616		20%
Corporate	(16,318)			(15,270)			(40,542)			(42,358)
Total EBITDA	$	238,511	32%	$	208,136	31%	$	643,767	32%	$	608,071	31%


	Three Months Ended				Nine Months Ended
	July 31, 2025		July 31, 2024		July 31, 2025		July 31, 2024
GAAP AS REPORTED
Operating profit	$	187,767	$	167,058	$	497,464	$	495,109
Other / interest expense - net	(28,643)		(17,624)		(82,715)		(57,700)
Net income	125,784		117,327		332,840		345,116
Diluted earnings per share	$	2.22	$	2.04	$	5.83	$	5.99

Shares outstanding - diluted	56,728		57,624		57,084		57,620

OPERATING PROFIT ADJUSTMENTS
Inventory step-up amortization	$	—	$	—	$	3,135	$	2,944
Acquisition costs	235		5,160		1,778		5,757
Severance and other	451		2,536		16,725		4,615
Divestiture and related charges	12,211		—		12,211		—

ACQUISITION AMORTIZATION OF INTANGIBLES	$	20,092	$	19,202	59,099		57,412


NON-OPERATING EXPENSE ADJUSTMENTS
Entity liquidation	$	—	$	—	$	988	$	—
Total adjustments	$	32,989	$	26,898	$	93,936	$	70,728

Adjustments net of tax	$	29,084	$	21,134	$	78,451	$	55,804

EPS effect of adjustments	$	0.51	$	0.37	$	1.37	$	0.97

NON-GAAP MEASURES-ADJUSTED NET INCOME AND ADJUSTED EARNINGS PER SHARE


Net income (1)	$	154,868	$	138,461	$	411,291	$	400,920
Diluted earnings per share (2)	$	2.73	$	2.41	$	7.20	$	6.96


	Year to Date
	July 31, 2025			April 30, 2025
Net cash provided by operating activities	$	516,264		$	278,292
Additions to property, plant and equipment	(49,002)			(37,439)
Free Cash Flow - Year to Date (1)	$	467,262		$	240,853

Free Cash Flow - Quarter to Date (1)	$	226,409

Net Income - Year to Date	$	332,840		$	345,116
Free Cash Flow Conversion - Year to Date (2)	140		%	70		%

Net Income - Quarter to Date	$	125,784
Free Cash Flow Conversion - Quarter to Date (2)	180		%

	Year to Date
	July 31, 2024			April 30, 2024
Net cash provided by operating activities	$	459,812		$	294,964
Additions to property, plant and equipment	(43,786)			(21,907)
Free Cash Flow - Year to Date (1)	$	416,026		$	273,057

Free Cash Flow - Quarter to Date (2)	$	142,969

Management uses certain non-GAAP measures, such as adjusted net income, adjusted EPS and EBITDA, internally to make strategic decisions, forecast future results, and evaluate the Company's current performance. Given management's use of these non-GAAP measures, the Company believes these measures are important to investors in understanding the Company's current and future operating results as seen through the eyes of management. In addition, management believes these non-GAAP measures are useful to investors in enabling them to better assess changes in the Company's core business across different time periods. Because non-GAAP financial measures are not standardized, it may not be possible to compare these financial measures to other companies' non-GAAP financial measures, even if they have similar names. Amounts may not add due to rounding.